The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
cancer‐specific survival
non‐muscle‐invasive bladder cancer
overall survival
progression‐free survival
recurrence‐free survival
statins
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy. A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression. A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013). Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University Grants Committee (UGC) Research Matching Fund
ID : 8601521
Organisme : General Research Fund/Early Career Scheme of the Research Grants Council, Hong Kong
ID : 14117421
Informations de copyright
© 2024 BJU International.
Références
Teoh JY, Huang J, Ko WY et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 2020; 78: 893–906
EAU Guidelines Office. EAU Guidelines. Edn. Presented at the EAU annual congress Milan. Arnhem, The Netherlands: EAU Guidelines Office, 2023
Teoh JY, Kamat AM, Black PC et al. Recurrence mechanisms of non‐muscle‐invasive bladder cancer ‐ a clinical perspective. Nat Rev Urol 2022; 19: 280–294
Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high‐risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43–51
Solsona E, Madero R, Chantada V et al. Sequential combination of mitomycin C plus bacillus Calmette‐Guérin (BCG) is more effective but more toxic than BCG alone in patients with non‐muscle‐invasive bladder cancer in intermediate‐ and high‐risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol 2015; 67: 508–516
Järvinen R, Marttila T, Kaasinen E et al. Long‐term outcome of patients with frequently recurrent non‐muscle‐invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette‐Guérin (BCG) or alternating BCG and interferon‐α2b instillations: prospective randomised FinnBladder‐4 study. Eur Urol 2015; 68: 611–617
Marttila T, Järvinen R, Liukkonen T et al. Intravesical bacillus Calmette‐Guérin versus combination of Epirubicin and interferon‐α2a in reducing recurrence of non‐muscle‐invasive bladder carcinoma: FinnBladder‐6 study. Eur Urol 2016; 70: 341–347
Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011; 215: 1–8
Chang WT, Lin HW, Lin SH, Li YH. Association of statin use with cancer‐ and noncancer‐associated survival among patients with breast cancer in Asia. JAMA Netw Open 2023; 6: e239515
An Y, Sun JX, Xu MY et al. Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: a systematic review and meta‐analysis of cohort studies. J Oncol 2022; 2022: 9275466
Khan S, Chang SH, Seyerle AA, Wang M, Hicks V, Drake BF. Post‐diagnostic metformin and statin use and risk of biochemical recurrence in veterans diagnosed with prostate cancer. Prostate 2023; 83: 1150–1157
Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta‐analysis of observational studies and randomized controlled trials. Drug Des Devel Ther 2019; 13: 405–422
Shao YY, Hsu CH, Yeh KH et al. Statin use is associated with improved prognosis of colorectal cancer in Taiwan. Clin Colorectal Cancer 2015; 14: 177–184.e4
Ferro M, Marchioni M, Lucarelli G et al. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non‐muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urol Nephrol 2021; 73: 796–802
Singla N, Haddad AQ, Passoni NM, Meissner M, Lotan Y. Anti‐inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high‐grade non‐muscle‐invasive bladder cancer. World J Urol 2017; 35: 105–111
Tsai HK, Katz MS, Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle‐invasive bladder cancer. Urology 2006; 68: 1188–1192
Zhou W, Liu H, Yuan Z et al. Targeting the mevalonate pathway suppresses ARID1A‐inactivated cancers by promoting pyroptosis. Cancer Cell 2023; 41: 740–756.e10
Wong GL, Hui VW, Tan Q et al. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Rep 2022; 4: 100441
Yip TC‐F, Wong VW‐S, Lai MS‐M et al. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol 2023; 78: 524–533
Chan JSK, Satti DI, Lee YHA et al. Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population‐based cohort study. Br J Cancer 2023; 128: 2253–2260
EAU Guidelines Office. EAU Guidelines. Arnhem, The Netherlands: EAU Guidelines Office, 2023
Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer‐current understanding and the prospect. Biomed Pharmacother 2020; 129: 110393
Thiel T, Ryk C, Chatzakos V et al. Secondary stimulation from bacillus Calmette‐Guérin induced macrophages induce nitric oxide independent cell‐death in bladder cancer cells. Cancer Lett 2014; 348: 119–125
Brandau S, Riemensberger J, Jacobsen M et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001; 92: 697–702
Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer 2016; 16: 718–731
Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 2005; 66: 1209–1212
Wang G, Cao R, Wang Y et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep 2016; 6: 35783
Parada B, Reis F, Pinto  et al. Chemopreventive efficacy of atorvastatin against nitrosamine‐induced rat bladder cancer: antioxidant, anti‐proliferative and anti‐inflammatory properties. Int J Mol Sci 2012; 13: 8482–8499
Kettunen K, Boström PJ, Lamminen T et al. Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient‐derived cells. Eur Urol 2019; 76: 430–434